<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817217</url>
  </required_header>
  <id_info>
    <org_study_id>SP2086-111</org_study_id>
    <nct_id>NCT02817217</nct_id>
  </id_info>
  <brief_title>The DDI Study of SP2086 and Valsartan</brief_title>
  <official_title>The Drug Interaction Study of SP2086 and Valsartan in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the potential PK interaction between SP2086 and
      Valsartan after multiple oral doses treatment in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of SP2086</measure>
    <time_frame>up to Day 9</time_frame>
    <description>Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of Valsartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of SP2086 acid</measure>
    <time_frame>up to Day 9</time_frame>
    <description>Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of Valsartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of Valsartan</measure>
    <time_frame>up to Day 9</time_frame>
    <description>Cmax (a measure of the body's exposure to Valsartan) will be compared. before and after administration of multiple doses of SP2086</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) of SP2086</measure>
    <time_frame>up to Day 9</time_frame>
    <description>AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of Valsartan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) of SP2086 acid</measure>
    <time_frame>up to Day 9</time_frame>
    <description>AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of Valsartan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) of Valsartan</measure>
    <time_frame>up to Day 9</time_frame>
    <description>AUC (a measure of the body's exposure to Valsartan) will be compared before and after administration of multiple doses of SP2086</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of volunteers with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to Day 9</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>SP2086 and Valsartan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP2086</intervention_name>
    <description>SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.</description>
    <arm_group_label>SP2086 and Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.</description>
    <arm_group_label>SP2086 and Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers with a body mass index (BMI, a measure of a person's weight in
             relation to height) between 19 and 26 kg/m2.

        Exclusion Criteria:

          -  History of diabetes

          -  History of heart failure or renal insufficiency

          -  Urinary tract infections, or vulvovaginal mycotic infections

          -  History of or current clinically significant medical illness as determined by the
             Investigator

          -  History of clinically significant allergies, especially known hypersensitivity or
             intolerance to lactose

          -  Known allergy to SP2086 or Valsartan or any of the excipients of the formulation of
             SP2086 or Valsartan
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>People's Liberation Army General Hospital of Chengdu Military Region</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolan Yong, docter</last_name>
      <phone>028-86571275</phone>
      <email>Yongxiaolan@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

